United BioSource Corporation Acquires Total Healthcare Group
United BioSource Corporation
(UBC), a wholly owned subsidiary of Medco Health Solutions, Inc., today announced the acquisition of Total Healthcare Group (THG), a London-based international consultancy serving clients in the biopharmaceutical industry. THG provides global payer research, strategic planning, and global value dossiers for biopharmaceutical products.
THG, together with UBC’s existing value strategy and research services, will be led by THG’s Dr. Robert Hollamby, who has been appointed Senior Vice President at UBC.
“Demonstrating value and providing evidence-based research that allows stakeholders in the health care market to make important economic decisions surrounding biopharmaceuticals and devices is crucial in the market place,” said UBC President Mark Clein. “UBC helps clients respond effectively to the evolving health care environment by researching, communicating, and demonstrating value in medicines. The addition of THG significantly expands our capabilities and geographic reach and allows us to launch a comprehensive practice that we expect to be a leader in the global biopharmaceutical industry.”
Results International served as THG’s financial advisor in this transaction.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
